socalTECH

NOVEMBER 14, 2013

San Diego-based medical device manufacturer Tandem Diabetes Care priced its IPO last night, saying it will offer up 8,000,000 shares of its common stock at $15.00 The company--which develops an insulin pump--will start trading today on the NASDAQ Global Market as TNDM.

Pricing 153

Pricing San Diego Startup Acquisition 153

socalTECH

MAY 16, 2013

San Diego-based Ambit Biosciences has priced its IPO, saying that it is offering up 8,125,000 shares of its common stock at $8.00 The company will start trading today on the NASDAQ Global Market as AMBI. Ambit priced well below its estimated initial public offering range, which had been set at between $13.00

Pricing 138

Pricing San Diego Startup Acquisition 138

socalTECH

APRIL 25, 2013

San Diego-based biopharmaceuticals developer Receptos has set the initial, estimated pricing range for its IPO, saying in a filing Thursday that it now expects its IPO pricing to be between $14.00 and $16.00

Pricing 153

Pricing San Diego Acquisition Funding 153

socalTECH

SEPTEMBER 18, 2020

San Diego-based green energy technology developer Nuvve , which is developing vehicle-to-grid load balancing technology, says it has started participating in California's wholesale energy markets, via an effort with the University of California San Diego.

San Diego 124

San Diego Pricing Design Sites 124

socalTECH

JULY 25, 2012

San Diego-based Peregrine Semiconductor , the developer of CMOS, RF integrated circuits, has set an estimated pricing range for its its IPO. According to a filing by the firm this morning, it is estimating a IPO price of between $14.00 The firm also said it has applied to list on the Nasdaq Global Market as PSMI.

Pricing 145

Pricing San Diego Equity Marketing 145

socalTECH

AUGUST 16, 2021

San Diego-based sales and marketing software developer Seismic has raised $170M in a Series G funding round, the company said this morning, and is now valued at $3 billion. Rowe Price, according to the company. Rowe Price, according to the company. Financial details of that acquisition were not announced.

San Diego 113

San Diego Coach Sales Training 113

socalTECH

MARCH 15, 2021

San Diego-based Longboard Pharmaceuticals, which is developing medicines for neurological diseases, raised $80M in its IPO last week, selling 5,000,000 shares of its common stock at a price of $16.00 The company is now trading on the Nasdaq Global Market as LBPH.

San Diego 113

San Diego Pricing Design Marketing 113

socalTECH

OCTOBER 9, 2020

San Diego-based sales enablement and marketing software developer Seismic said this week that it has named a new Chief Product Officer. Rowe Price READ MORE>>. Mantipragada also previously served at First Data and SAP. Seismic recently raised another $92M in funding, which valued the company at approximately $1.6

Product 124

Product Southern California San Diego Sales 124

socalTECH

SEPTEMBER 10, 2020

San Diego-based sales enablement and marketing software developer Seismic said this morning that it has named Heather Cole as the company Vice President, Market Growth. Cole was previously VP and Research Director at Forrester-SiriusDecisions. Seismic is venture backed by Lightspeed Venture Partners, T.

San Diego 113

San Diego Equity Research Software Development 113

socalTECH

APRIL 8, 2019

San Diego-based Guardion Health Sciencs , which is developing "condition-specific medical foods and testing technologies" for the ocular health market, has raised $5.0M The company priced its IPO on Friday, selling 1,250,000 shares of its common stock at a price of $4.00 in a small IPO. READ MORE>>.

San Diego 113

San Diego Pricing Capital Marketing 113

socalTECH

MAY 28, 2019

San Diego-based Cibus , a developer of gene editing tools being aimed at use in plant breeding, has pulled its IPO paperwork, saying in a filing that it has decided "not to proceed with the initial public offering of its securities at this time." Cibus had set an estimated initial pricing range of $14.00 READ MORE>>.

San Diego 113

San Diego Pricing Tool Invest 113

socalTECH

SEPTEMBER 17, 2018

San Diego-based Senomyx , a developer of artificial flavoring ingredients and sweeteners for the beverage and food market, has been acquired by Switzerland's Firmenich , in a deal worth approximately $72.5M. The deal is an approximately 43 percent premium over the closing price of Senomyx on September 14th.

San Diego 113

San Diego Pricing Marketing Develop 113

socalTECH

AUGUST 2, 2010

San Diego-based Trius Therapautics has slashed its IPO offering price, saying today in a filing with the SEC that it will offer 10,000,000 shares of its common stock at $5.00 The firm, which will list on the Nasdaq Global Market as TSRX, had initially said it would sell 6,000,000 shares of its stock at between $12.00

Pricing 150

Pricing San Diego Acquisition Marketing 150

socalTECH

SEPTEMBER 23, 2019

A portfolio company of San Diego-based biopharmaceuticals venture investor Versant Ventures is getting set for its IPO this week. Aprea Therapeutics said that estimates its IPO will price between $14.00 Aprea--based in Boston and Sweden--says it has applied to list on the Nasdaq Global Select Market under the symbol APRE.

San Diego 113

San Diego Pricing Invest Marketing 113

socalTECH

SEPTEMBER 29, 2020

San Diego-based Seismic , which develops sales enablement and marketing software, has joined the unicorn club, saying this morning that it has raised $92M in a Series F funding, which values the company at approximately $1.6 Rowe Price, its existing investors. Seismic has now raised a total of $270M in funding.

San Diego 113

San Diego Sales Pricing Activity 113

socalTECH

APRIL 14, 2017

San Diego-based gene therapy developer Tocagen rose in its IPO this morning, after pricing at $10.00 per share, after its debut on the NASDAQ Global Select Market as TOCA. Tocagen is developing clinical-stage, cancer-selective gene therapy products. The company now has a market cap of approximately $187M.

San Diego 127

San Diego Pricing Marketing Product 127

socalTECH

SEPTEMBER 8, 2014

San Diego-based Anametrix , which develops marketing analytics software, said Monday that it has tied its software to Tableau , the developer of visual data analytics tools. Price of the new product was not announced. Anametrix is led by Pelin Thorogood. READ MORE>>.

San Diego 178

San Diego Software Pricing Tool 178

socalTECH

NOVEMBER 4, 2010

San Diego-based Zogenix has updated its S-1, saying this morning the firm intends to offer 6 million shares of its common stock on the Nasdaq Global Market as ZGNX. The firm also said it currently estimates the firm's initial offering price at between $12.00 and $14.00 Zogenix had filed for an IPO in September.

Pricing 140

Pricing San Diego Acquisition Marketing 140

socalTECH

AUGUST 3, 2010

San Diego-based Trius Therapeutics is set to hit the markets today, after pricing its IPO last night. Trius will trade on the NASDAQ Global Market under the symbol TSRX. The IPO is being underwritten by Citigroup Global Markets, Piper Jaffray & Co., and $14.00 Canaccord Genuity Inc. and JMP Securities.

Marketing 140

Marketing San Diego Pricing Acquisition 140

TechCrunch LA

DECEMBER 8, 2020

He did note that in the four markets where the company has gone live since launching its business in January 2019 — San Diego, Los Angeles, the Inland Empire , and Sacramento — has yielded an annualized revenue run rate of over $400 million in gross merchandise value (the total value of home sales transacted on its platform).

Sales 282

Sales Demand San Diego Funding 282

socalTECH

AUGUST 25, 2016

San Diego-based biopharmaceutiacls developer Viking Therapeutics says it has raised $12.5M per share, with the remaining $12M to be purchase over the next 30 months at prices based on the market price. Viking Therapeutics is developing treatments for metabolic and endocrine disorders. READ MORE>>.

San Diego 100

San Diego Pricing Capital Funding 100

socalTECH

NOVEMBER 27, 2017

San Diego-based Odonate Therapeutics , a startup that says it is hoping to develop chemotherapy drugs, is looking to raised $182.5M in an IPO on the NASDAQ Global Select Market. The company has set its estimated IPO price range at between $24.00 and $27.00

San Diego 113

San Diego Pricing Capital Funding 113

socalTECH

MAY 9, 2013

San Diego-based biopharmaceuticals developer Receptos is trading flat after its initial public offering, after pricing last night at $14.00 The developer of biopharmaceuticals for treating immune and metabolic diseases priced at the low end of its estimated IPO range, which was $14.00 READ MORE>>.

San Diego 159

San Diego Pricing Venture Capital Acquisition 159

socalTECH

SEPTEMBER 3, 2014

San Diego-based biopharmaceuticals developer Viking Therapeutics has set the estimated pricing for its IPO, saying in a filing Tuesday that it expects to price its IPO at between $10.00 The company has applied to list as VKTX on the NASDAQ Global market. and $12.00 in its offering. READ MORE>>.

San Diego 138

San Diego Pricing Research Acquisition 138

socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M Anaptys priced its IPO on Wednesday night at $15.00 The company now trades as ANAB on the NASDAQ Global Select Market. in its IPO, and closed up slightly in its first day of trading on Thursday. READ MORE>>.

Avalon 100

Avalon San Diego Pricing Invest 100

socalTECH

AUGUST 13, 2014

San Diego-based biopharmaceuticals firm Otonomy was up today in early trading, after pricing 6.25 today after its debut on the NASDAQ Global Market as OTIC. The company priced at the high end of its initial estimated IPO range, which was $14.00 The company is developing treatments for disorders of the inner ear.

Avalon 138

Avalon San Diego Pricing Acquisition 138

Xconomy

JULY 31, 2020

The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II.

Pricing 72

Pricing Acquisition Capital Marketing 72

Xconomy

NOVEMBER 19, 2018

Cibus, which has developed a proprietary gene-editing technology that tweaks crops’ DNA to improve yield, is planning to make its public market debut. The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday.

San Diego 72

San Diego Research Startup Pricing 72

socalTECH

OCTOBER 1, 2013

San Diego-bsaed Fate Therapeutics , which is developing biopharmaceuticals base don adult stem cells to treat a number of orphan diseases, is up slightly in trading after its initial public offering this morning. Fate Therapeutics priced at $6.00 The company is now trading as FATE on the NASDAQ Global Market.

San Diego 157

San Diego Pricing Acquisition Marketing 157

Xconomy

APRIL 17, 2019

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. million shares at $18 apiece, raising $166.5 million before discounts, commissions, and offering expenses.

Pricing 57

Pricing Demand Marketing Develop 57

socalTECH

MAY 7, 2015

San Diego-based biotech developer aTyr Pharma is debuting in its IPO this morning, after pricing its IPO at $14.00 the company will trade as LIFE on the NASDAQ Global Market starting this morning. per share last night. The company raised $75M in the offering.

San Diego 100

San Diego Pricing Invest Marketing 100

socalTECH

JULY 21, 2015

San Diego-based MicroPower Technologies , which develops wireless, video surveillance systems, said yesterday that it has launched a new certification and training program for its partners. MicroPower said resellers who complete the course gain access to marketing collateral, presentations, and preferred pricing.

Training 100

Training Tech Coast Angels San Diego Incubator 100

socalTECH

MAY 19, 2014

San Diego-based Sophiris Bio said this morning that it has raised $2M in funding from Aspire Capital Fund, and received commitments of up to $13M more, to help fund its efforts to develop a treatment for localized prostate cancer. The company said the news fund will provide additional "financial flexibility" for the company.

San Diego 138

San Diego Venture Capital News Pricing 138

socalTECH

MARCH 20, 2014

Los Angeles-based online advertising technology developer Rubicon Project set the pricing range for its initial public offering Thursday, saying that it hopes to offer 6,770,995 shares of its common stock at between $15.00 RBC Capital Markets, Needham & Company, Oppenheimer & Co, and Luma Securities. and $17.00

Clearstone 164

Clearstone Southern California Advertising San Diego 164

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. The company joins the public markets with four product candidates in its pipeline, all topical non-steroidal treatments being developed for seven dermatological indications.

Westlake Village 114

Westlake Village Pricing Develop Development 114

socalTECH

AUGUST 21, 2012

Publicly held biopharmaceuticals firm MediciNova , which is based in San Diego, said last night that it has raised $20M in funding in a deal with Aspire Capital Fund, LLC. Medicinova said that Aspire will purchase the $20M in common stock at market prices.

San Diego 140

San Diego Pricing Capital Funding 140

socalTECH

JANUARY 20, 2015

San Diego-based biopharmaceuticals developer Tracon Pharmaceuticals said in a regulatory filing today that it is estimated its IPO pricing at between $12.00 The company--which filed for an IPO over the holidays--is looking to raised $57.96M on the NASDAQ Global Market as TCON. and $14.00 READ MORE>>.

San Diego 100

San Diego Acquisition Pricing Invest 100